Deletions of the long arm of chromosome 11 (11q) have been noted in primary
neuroblastomas, but a comprehensive analysis has not been performed. There
fore, we analysed 331 neuroblastomas (295 sporadic, 15 familial and 21 tumo
r-derived cell Lines) to determine the prevalence of 11q allelic deletions,
to map the location of a putative tumor suppressor gene and to perform cli
nical correlative studies. Assays for loss of heterozygosity (LOH) were per
formed at 24 microsatellite loci spanning 11q, LOH was observed at multiple
11q loci in 129/295 (44%) sporadic neuroblastomas, 5/15 (33%) familial neu
roblastomas, and 5/21 (24%) neuroblastoma cell lines. A single region of 2.
1 cM within 11q23,3, flanked by markers D11S1340 and D11S1299, was deleted
in all specimens with 11q LOH, Allelic loss at 11q23 was inversely related
to MYCN amplification (P < 0,001), Within the subset of cases with a single
copy of MYCN 11q LOH was associated with advanced stage disease (P = 0,008
), unfavorable histopathology (P = 0,042), and decreased overall survival p
robability (P = 0,008), However, 11q LOH was not independently prognostic i
n multivariate analyses, These data support the hypothesis that a tumor sup
pressor gene mapping within 11q23,3 is commonly inactivated during the mali
gnant evolution of a large subset of neuroblastomas, especially those with
unamplified MYCN.